ORTEXORTEX News
Live short interest, options flow, and signals — free on ORTEX.Sign up free →
Market Commentary

Chips, Consultants, and a $600M Insider Exit

By ORTEX News · Edited by , Editor, ORTEX News1 min read

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

AI Hardware in Focus

The week kicks off with semiconductors dominating sentiment. SMCI surged Monday on short covering. Short interest sits at 13.4% of free float — down from a June peak near 15.9%. Options traders are betting on more upside. Short-dated calls stack up through June 26. NVDA shows different dynamics: short interest is just 1.25% of free float. Yet NVDA carries the densest options chain in the sector, with zero-day contracts active today. MU reports earnings this Wednesday after the close. Memory chip demand for AI servers is the key focus. Options activity around the June 24–26 dates is heavy.

Accenture Takes Analyst Fire

ACN is under broad Wall Street pressure. TD Cowen cut to Hold with a $150 target, down from $258. Truist also maintained Hold, trimming to $150. RBC and Susquehanna made sharp cuts as well. The concern is consistent: AI disruption is hurting consulting demand. ACN's market cap stands at $78.3 billion.

Insiders Cash Out

The biggest insider move this week came from WMT. The Walton Family Holdings Trust sold $535 million in shares on June 16. That's 4.4 million shares at roughly $121 each. AMAT executives also unloaded heavily. CEO Gary Dickerson sold $49.2 million. CTO and board members added another $31 million. Total AMAT insider sales topped $80 million in two days.

Short Squeeze Watch

HTZ is flashing squeeze signals. Utilization hit 95.3%. Availability collapsed to just 5.7% of short interest. With 44% of free float shorted, any positive catalyst could force rapid covering. Separately, Tradeweb Markets saw cost to borrow surge 131% in one week to 0.44%. Short supply is tightening fast.

European Pharma Win

Arrowhead Pharmaceuticals received European Commission marketing authorisation today for REDEMPLO. The drug treats familial chylomicronemia syndrome. It's a clean regulatory win and a rare piece of positive drug news to close the week.

Stocks in this article

How this article was generated

Generated
22 Jun 2026, 16:51
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowORTEX Alpha signalsORTEX Alpha signalsAnalyst consensus

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.